The PD-1 receptor, a major immune checkpoint inhibitor whose signaling is the target of multiple blockbuster anticancer drugs, differs functionally between rodents and humans in previously unknown ...

Researchers at the Johns Hopkins Kimmel Cancer Center and Bloomberg-Kimmel Institute for Cancer Immunotherapy have developed ...

近日，上海交通大学附属胸科医院陆舜教授团队在SCIENCE CHINA Life Sciences (《中国科学：生命科学》英文版) 发表题为“Effectiveness of PD-1/PD-L1 inhibitors in ...

Perioperative chemotherapy with either S-1 or 5-fluorouracil plus oxaliplatin and docetaxel for locally advanced gastric or gastroesophageal junction adenocarcinoma: A prospective trial and matched ...

It is the second drug in the PD-1/PD-L1 inhibitor class to be cleared in a subcutaneous injection form by the FDA after Roche's Tecentriq Hybreza (atezolizumab and hyaluronidase) – which got a ...

PhD The multicenter study showed that addition of the programmed cell death protein 1 (PD-1) inhibitor sintilimab to neoadjuvant chemoradiotherapy achieved a pathological complete response (pCR ...

The Phase III trial builds on findings from prior findings that indicated Anktiva can restore T-cell function and improve ...

The PD-1 checkpoint inhibitor was approved back in April 2021 through an accelerated approval process based on phase 1 data from GSK's GARNET trial. This approval was based on A1 expansion data ...

Leo Pharma has stepped up to commercialize toripalimab in Europe, inking a deal with Shanghai Junshi Biosciences to secure ...

BeiGene’s trials suggest that this mechanism, combined with chemotherapy, offers survival benefits in PD-L1-expressing cancers. Tevimbra is part of a competitive PD-1 inhibitor market ...